424
Participants
Start Date
October 23, 2023
Primary Completion Date
August 31, 2026
Study Completion Date
April 30, 2027
Jada® System
This is a U.S. FDA-cleared device intended for treatment of PPH when conservative management is warranted. The device is made of medical grade silicone. The distal end, which is placed in the uterus, is an elliptical loop. The circular cervical seal, just outside the external cervical os, is filled with 60 - 120 mL sterile water. Low-level vacuum (80 ± 10 mm Hg) is applied and pooled blood is evacuated from the uterus as it collapses. Once there is no bleeding, the device remains in the uterus for at least 1 hour. The suction is then disconnected, the seal emptied of water, the device left in place, and the patient monitored for an additional 30 minutes. If bleeding remains controlled, the device is removed. If bleeding is uncontrolled with the Jada® System patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
Standard care
Patients in this group will receive care according to the treatment algorithm for PPH from uterine atony at the two teaching hospitals in Ghana. Possible interventions include additional uterotonics, tranexamic acid, and condom catheter balloon uterine tamponade. If bleeding is uncontrolled, patients will have surgical intervention with options of uterine vascular ligation, uterine compression sutures or hysterectomy.
RECRUITING
Komfo Anokye Teaching Hospital, Kumasi
RECRUITING
Korle-bu Teaching Hospital, Accra
Washington University School of Medicine
OTHER
University of Ghana
OTHER
Kwame Nkrumah University of Science and Technology
OTHER
Women and Infants Hospital of Rhode Island
OTHER